Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Taisuke Uehara
Final Results of a Phase 2, Open-Label Study of Indisulam, Idarubicin, and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Cancer
Cancer Research
Oncology
Related publications
Idarubicin, Cytarabine and Pravastatin as Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Phase I Trial of SAR103168, a Novel Multi-Kinase Inhibitor, in Patients With Refractory/Relapsed Acute Leukemia or High-Risk Myelodysplastic Syndrome
Leukemia and Lymphoma
Cancer Research
Oncology
Hematology
High Dose Cytarabine Plus Gemtuzumab Ozogamicin for Patients With Relapsed or Refractory Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19902
Leukemia Research
Cancer Research
Oncology
Hematology
Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
A Phase II Study of AZD2171 (Cediranib) in the Treatment of Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Leukemia and Lymphoma
Cancer Research
Oncology
Hematology
A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients With Relapsed/Refractory Acute Myeloid Leukemia
Advances in Hematology
Hematology
Low Dose Cytarabine and Cladribine for Treatment of Relapsed or Refractory Acute Myeloid Leukemia: Clinical Experience
Klinicheskaya Onkogematologiya/Clinical Oncohematology
Oncology
Hematology
Enduring Efficacy and Tolerability of Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma ( GEN 503): Final Results of an Open‐label, Phase 1/2 Study
British Journal of Haematology
Hematology
